Neuropsychological outcome following intrauterine exposure to valproate;Neuropsychologisches outcome nach intrauteriner valproat-exposition. Eine stellungnahme der deutschen gesellschaft für epileptologie

Nervenarzt

Volumn 77, Issue 8, 2006, Pages 901-911

  Schmitz, B ^a   Kramer G ^b   Helmstadter C ^c   Jokeit, H ^b   Koch, S ^d   Luef, G ^e   Schaefer, C ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SWISS EPILEPSY CENTER   (Switzerland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Institut für Neuropsychologische Diagnostik und Bildgebung ^*  (Germany)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Advantages vs risk; Indication; Intrauterine exposure; Neuropsychological developmental disturbances; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; PRIMIDONE; VALPROIC ACID;

BEHAVIOR DISORDER; DEVELOPMENTAL DISORDER; DRUG INDICATION; EPILEPSY; HUMAN; INTELLIGENCE QUOTIENT; NERVE CELL DIFFERENTIATION; NEUROPSYCHOLOGY; PRENATAL EXPOSURE; REVIEW; RISK BENEFIT ANALYSIS;

FEMALE; GERMANY; HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

EID: 33747066930     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-006-2085-z     Document Type: Review

References (39)

1. Morrow J, Russell A, Guthrie E et al. (2005) Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193-198
2. Vajda FJ, O'Brien TJ, Hitchcock A et al. (2004) Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 11:854-858
3. Vajda FJ, Eadie MJ (2005) Maternal valproate dosage and foetal malformations. Acta Neurol Scand 112:137-143
4. Wyszynski DF, Nambisan M, Surve T et al. (2005) Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64:961-965
5. Artama M, Isojärvi JI, Raitanen J et al. (2004) Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 159:1057-1063
6. Adab N, Jacoby A, Smith D et al. (2001) Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70:15-21
7. Adab N, Kini U, Vinten J et al. (2004) The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75:1575-1583
8. Vinten J, Adab N, Kini U et al. (2005) Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64:949-954
9. Gaily E, Kantola-Sorsa E, Hiilesmaa V et al. (2004) Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62:28-32
10. Eriksson K, Viinikainen K, Mönkkönen A et al. (2005) Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65:189-200
11. Meador KJ, Zupang ML (2004) Neurodevelopmental outcomes of children born to mothers with epilepsy. Cleve Clin J Med 71(Suppl 2):S38-S41
12. Meador K, Baker G, Clayton Smith J et al. (2005) Preliminary results from the NEAD (Neurodevelopmental Effects ofAntiepileptic Drugs) study group. First Annual AES Pregnancy Outcomes Forum; American Epilepsy Society 58th Annual Meeting
13. Hanson JW, Myrianthopoulos NC, Harvey MA et al. (1976) Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 89:662-668
14. Shapiro S, Hartz SC, Siskind V et al. (1976) Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1:272-275
15. Hill RM, Verniaud WM, Horning MG (1974) Infants exposed in utero to antiepileptic drugs - a prospective study. Am J Dis Child 127:645-653
16. Vert P, Andre M, Deblay MF (1979) Infants of epileptic mothers. In: Stern I, Oh W, Friis-Hansen B (eds) Intensive care in the newborn II. Paris-New York. Masson 34:347-360
17. Leavitt MD, Yerby MS, Robinson N (1992) Epilepsy in Pregnancy: developmental outcome of offspring at 12 months. Neurology 42(S5):141-143
18. Scolnik D, Nulman I, Rovet J et al. (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767-770
19. Lösche G, Steinhausen H-C, Koch S et al. (1994) The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 83:961-966
20. Koch S, Titze K, Zimmermann RB et al. (1999) Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 40:1237-1243
21. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ (2000) Association of prenatal phenobarbital and phenytoin exposure with small head sizes at birth and with learning problems. Acta Paediatr 89:533-541
22. DiLiberti JH, Farndon PA, Dennis NR et al. (1984) The fetal valproate syndrome. Am J Med Genet 19:473-481
23. Robert E, Lofkvist E, Mauguiere F (1984) Valproate and spina bifida. Lancet 2(8416):1392
24. Jäger-Roman E, Deichl A, Jakob S (1986) Fetal growth, major malformations, and minor anomalies in infants, born to women receiving valproic acid. J Pediatr 108:997-1003
25. Koch S, Titze K, Treuter S (2000) Maternal use of valproate during pregnancy: Risk of major malformations and brain disorders. In: Schmitz B, Sander T (eds) Juvenile myoclonic epilepsy: the Janz syndrome. Wrightson Biomedical Publishing, Petersfield-Philadelphia, pp 121-128
26. Arndt TL, Stodgell CJ, Rodier PM (2005) The teratology of autism. Int J Dev Neurosci 33:189-199
27. Christianson AL, Chesler N, Kromberg JG (1994) Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 36:361-369
28. Williams PG, Hersh JH (1997) A male with fetal valproate syndrome and autism. Dev Med Child Neurol 39:632-634
29. Williams G, King J, Cunningham M et al. (2001) Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 43:202-206
30. Moore SJ, Turnpenny P, Quinn A et al. (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37:489-497
31. Miyazaki K, Narita N, Narita M (2005) Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 23:287-297
32. Schneider T, Turczak J, Przewlocki R (2005) Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 31:36-46
33. Narita N, Kato M, Tazoe M et al. (2002) Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 52:576-579
34. Ingram JL, Peckham SM, Tisdale B et al. (2000) Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 22:319-324
35. Rodier PM, Ingram JL, Tisdale B et al. (1997) Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 11:417-422
36. Gaily E, Kantola-Sorsa E, Granstrom ML (1988) Intelligence of children of epileptic mothers. J Pediatr 13:677-684
37. Barf HA, Verhoef M, Jennekens-Schinkel A et al. (2003) Cognitive status of young adults with spina bifida. Dev Med Child Neurol 45:813-820
38. Gaus V, Coban I, Kretz R et al. (2005) EURAP-Anfallskontrolle in der Schwangerschaft unter Lamotrigin, Carbamazepin und Valproat in Monotherapie. Z Epileptol 18:129
39. Lamotrigine Pregnancy Registry (2006) Interim Report. Data on file